Telix Pharmaceuticals Logo
Telix Pharmaceuticals Logo
  • Our Company
    • Our Company
    • Purpose, Mission & Values
    • Board & Management
    • Our Technology
    • Sustainability
  • Our Portfolio
    • Our Portfolio
    • Disease Areas
      • Prostate Cancer
      • Kidney Cancer
      • Brain Cancer
      • Musculo-skeletal cancers
    • Clinical Trials
    • Illuccix® & Gozellix®
    • Pipeline
    • Research & Innovation
  • Investor Centre
  • News & Views
  • Careers
    • Careers
    • Find a job
Header Image Frame Header Image Frame

Home Clinical Page 9

News & Views

Latest News

Category: Clinical

See all

Telix Progresses Novel Lung and Ovarian Cancer Theranostic APOMAB®

Clinical, News,

Telix extends partnership with AusHealth relating to APOMAB®, a novel theranostic being investigated in lung and ovarian...

Read more

Telix’s TLX66 in Phase II Academic Study of Pediatric Leukemia

Clinical, News,

Telix announces Phase II academic study of TLX66 in children with high-risk...

Read more

First Patient Dosed in CUPID Study of Telix’s Targeted Alpha Therapy Candidate for Prostate Cancer

Clinical, News,

Telix announces the first patient has been dosed in its ‘CUPID’ Phase I study of TLX592 in patients with advanced prostate...

Read more

ZIRCON Phase 3 Renal Cancer Imaging Study: Progress Update

Clinical, News,

Progress update on the ZIRCON Phase 3 study for the imaging of renal cancer with Positron Emission Tomography...

Read more

First Patient Dosed in Clinical Study of TLX250-CDx in Bladder Cancer

Clinical, News,

Telix announces that a first patient has been dosed in a Phase I study of TLX250-CDx in patients with bladder...

Read more

IPAX-1 (TLX101 for Glioblastoma Therapy) Clinical Trial Update

Clinical, News,

Telix announces preliminary safety data from the IPAX-1 Ph I/II study, with a follow-on study being planned in front-line...

Read more

TLX66 Meets Study Objectives in Patients with AL Amyloidosis

Clinical, News,

Telix announces bone marrow conditioning investigational candidate TLX66 has met study objectives, demonstrating the initial safety profile in patients with AL...

Read more

First Patient Dosed in Japanese Prostate Cancer Imaging Study

Clinical, News,

Telix announces the first patient has been dosed in a clinical study in Japan using Telix’s investigational prostate cancer imaging product,...

Read more

Telix Commences Phase III Clinical Trial of Prostate Cancer Therapy

Clinical, News,

Telix has been granted HREC approval and received CTN clearance by the TGA to commence a Phase III study of the Company’s prostate cancer therapy candidate TLX591, in patients with advanced...

Read more

Japanese Renal Cancer Imaging Trial Meets Study Objectives

Clinical, News,

Telix announces the Company’s ZIRDAC-JP study of its renal cancer imaging product demonstrates safety and tolerability in Japanese...

Read more

Posts pagination

1 … 8 9 10 … 12

Subscribe

* indicates required

By subscribing, you are agreeing to the terms of our Global Privacy Policy and provide consent to receive updates from Telix”

Telix Pharmaceuticals Logo
  • Our Company
  • Contact
  • Our Portfolio
  • Careers
  • Investor Centre
  • News & Views

© Telix Pharmaceuticals Limited. 55 Flemington Road, North Melbourne, VIC 3051, Australia.

The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.
This website is intended for corporate communication purposes only and is not intended as promotion or advertising to any audience in any country worldwide.

Privacy Policy. Terms of Use. Cookies Policy. Privacy Settings